None listed
Conditions
Interventions
Drug : Patients who consent to participate in the study are randomly assigned in a 1:1 ratio to either the experimental group or the control group. The investigational drug is administered for 6 weeks
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) Underwent radiofrequency ablation for atrial fibrillation. ii) Age 19 to 90 years inclusive.
Exclusion criteria
Exclusion criteria: i) Patients with moderate or severe liver impairment, or renal impairment (Serum Cr > 1.5 mg/dl). ii) Patients with cognitive impairments that make it difficult to understand the study. iii) Pregnant or breastfeeding patients, or those not willing to maintain contraception during the study period. iv) Patients with hypersensitivity to fexuprazan, or those with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. v) Patients taking contraindicated medications such as atazanavir, nelfinavir, or rilpivirine. vi) Patients who have taken Proton Pump Inhibitors (PPI) or PCAB agents for gastroesophageal reflux disease within 2 weeks prior to study enrollment. vii) Other patients for whom the clinical administration of PCAB is considered difficult.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Esophagogastric symptom questionnaire score ;Esophagogastric symptom questionnaire score | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence rate of esophagoatrial fistula;New prescription of gastrointestinal medication;Other gastrointestinal complications | — |
Countries
Korea, Republic of
Contacts
Public ContactYoung Choi
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed